OTCMKTS:NSPX Inspyr Therapeutics (NSPX) Stock Price, News & Analysis → Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad) Free NSPX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume29.64 million shsAverage Volume13.19 million shsMarket Capitalization$1.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Inspyr Therapeutics alerts: Email Address Ad Traders AgencyNVIDIA is a laughing stock compared to thisYou’ve probably read about NVIDIA’s recent earnings blowout… Where it revealed that thanks to demand for AI, its future earnings will crush previous expectations. The markets reacted by sending NVIDIA’s stock surging by almost 25% in a single day… An impressive feat when you consider it was already a $700+ billion stock before that surge. If you already owned NVIDIA stock before the jump – congratulations… But if you didn’t, don’t worry… Because I’ve just discovered an undercover AI stock that I believe could do 300 times better than NVIDIA.So just click here to get your hands on my AI Wonder Stock About Inspyr TherapeuticsInspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.Read More Ad Huge AlertsThis 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!Sign Up for the Live Broadcast here NSPX Stock News HeadlinesApril 4, 2024 | seekingalpha.comEWTX Edgewise Therapeutics, Inc.March 4, 2023 | benzinga.comTG Therapeutics Stock (NASDAQ:TGTX), Analyst Ratings, Price Targets, PredictionsMay 9, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.October 12, 2021 | ca.finance.yahoo.comInspyr Therapeutics Announces New Holding Company Structure and Reverse Stock SplitSee More Headlines Receive NSPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inspyr Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2017Today5/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:NSPX CUSIPN/A CIK1421204 Webwww.genspera.com Phone(818) 597-7552FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,300,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,354.49% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / BookN/AMiscellaneous Outstanding Shares543,152,000Free FloatN/AMarket Cap$1.47 million OptionableNot Optionable Beta-17.33 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesSilvestre RaulPresident, Chief Executive Officer & DirectorMichael ElliottVice President-Clinical OperationsKey CompetitorsLucy Scientific DiscoveryNASDAQ:LSDIPanbela TherapeuticsNASDAQ:PBLANeuBase TherapeuticsNASDAQ:NBSEGRI BioNASDAQ:GRIInMed PharmaceuticalsNASDAQ:INMView All Competitors NSPX Stock Analysis - Frequently Asked Questions How were Inspyr Therapeutics' earnings last quarter? Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) released its quarterly earnings data on Monday, August, 14th. The company reported ($26.25) earnings per share (EPS) for the quarter. When did Inspyr Therapeutics' stock split? Shares of Inspyr Therapeutics reverse split on Tuesday, October 12th 2021. The 1-75 reverse split was announced on Tuesday, October 12th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 12th 2021. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Inspyr Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inspyr Therapeutics investors own include Hon Hai Precision Industry (HNHPF), iBio (IBIO), Knight-Swift Transportation (KNX), Danaher (DHR), Co-Diagnostics (CODX), Cleveland BioLabs (CBLI), Cloudcall Group (CALL), Blink Charging (BLNK) and BIO-key International (BKYI). How do I buy shares of Inspyr Therapeutics? Shares of NSPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NSPX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThis 1 Biotech Stock has been shocking the marketsHuge AlertsThings Are Not Normal in America – Here’s What to DoStansberry Research1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inspyr Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.